Scpharmaceuticals Company Top Insiders
SCPH Stock | USD 3.41 0.06 1.79% |
Under 67% of Scpharmaceuticals' corporate insiders are selling. The analysis of insiders' sentiment of trading Scpharmaceuticals stock suggests that many insiders are alarmed at this time. Scpharmaceuticals employs about 135 people. The company is managed by 6 executives with a total tenure of roughly 10 years, averaging almost 1.0 years of service per executive, having 22.5 employees per reported executive.
John Tucker CEO President CEO, Director |
Scpharmaceuticals' Insider Buying Vs Selling
33
Selling | Buying |
Latest Trades
2022-11-25 | Orbimed Advisors Llc | Acquired 762380 @ 5.25 | View | ||
2022-10-10 | 5Am Partners Iv, Llc | Disposed 562466 @ 4.09 | View | ||
2022-10-06 | 5Am Partners Iv, Llc | Disposed 37534 @ 5.02 | View | ||
2022-09-06 | 5Am Partners Iv, Llc | Disposed 26622 @ 5.52 | View | ||
2022-04-11 | 5Am Partners Iv, Llc | Disposed 270000 @ 5 | View | ||
2021-12-03 | John H Tucker | Acquired 10000 @ 3.96 | View |
Monitoring Scpharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Scpharmaceuticals |
Scpharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Scpharmaceuticals' future performance. Based on our forecasts, it is anticipated that Scpharmaceuticals will maintain a workforce of under 140 employees by December 2024.Scpharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4202) % which means that it has lost $0.4202 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6689) %, meaning that it created substantial loss on money invested by shareholders. Scpharmaceuticals' management efficiency ratios could be used to measure how well Scpharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.61. The Scpharmaceuticals' current Return On Capital Employed is estimated to increase to -0.65. As of now, Scpharmaceuticals' Non Currrent Assets Other are increasing as compared to previous years. The Scpharmaceuticals' current Other Current Assets is estimated to increase to about 3.8 M, while Total Assets are projected to decrease to under 90.6 M.The current Common Stock Shares Outstanding is estimated to decrease to about 22.2 M. The current Net Loss is estimated to decrease to about (34.8 M)
Scpharmaceuticals Workforce Comparison
Scpharmaceuticals is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,025. Scpharmaceuticals retains roughly 135 in number of employees claiming about 13% of equities under Health Care industry.
Scpharmaceuticals Profit Margins
The company has Profit Margin (PM) of (2.65) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.81) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.81.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.58 | 0.65 |
|
|
Scpharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Scpharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Scpharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Scpharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 2.0 | 6 | 3 | 532,237 | 21,792 |
2024-03-01 | 2.5 | 5 | 2 | 444,520 | 5,969 |
2022-12-01 | 0.2857 | 4 | 14 | 932,630 | 1,252,538 |
2022-06-01 | 3.25 | 13 | 4 | 211,900 | 490,096 |
2021-03-01 | 1.0 | 3 | 3 | 193,850 | 152,033 |
2020-06-01 | 6.5 | 13 | 2 | 2,098,809 | 52,538 |
2020-03-01 | 4.0 | 4 | 1 | 715,986 | 1,981 |
2018-09-01 | 2.0 | 2 | 1 | 24,496 | 41,781 |
2017-12-01 | 0.8077 | 21 | 26 | 17,890,386 | 119,851,458 |
Scpharmaceuticals Notable Stakeholders
A Scpharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Scpharmaceuticals often face trade-offs trying to please all of them. Scpharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Scpharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John Tucker | President CEO, Director | Profile | |
John PharmD | Senior Affairs | Profile | |
Rachael Nokes | Principal Accounting Officer | Profile | |
Katherine Taudvin | Director Relations | Profile | |
Michael Hassman | Senior Operations | Profile | |
Steve Parsons | Senior Commercial | Profile |
About Scpharmaceuticals Management Performance
The success or failure of an entity such as Scpharmaceuticals often depends on how effective the management is. Scpharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Scpharmaceuticals management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Scpharmaceuticals management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.58) | (0.61) | |
Return On Capital Employed | (0.68) | (0.65) | |
Return On Assets | (0.58) | (0.61) | |
Return On Equity | (1.47) | (1.40) |
Scpharmaceuticals Workforce Analysis
Traditionally, organizations such as Scpharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Scpharmaceuticals within its industry.Scpharmaceuticals Manpower Efficiency
Return on Scpharmaceuticals Manpower
Revenue Per Employee | 100.7K | |
Revenue Per Executive | 2.3M | |
Net Loss Per Employee | 406K | |
Net Loss Per Executive | 9.1M | |
Working Capital Per Employee | 591.1K | |
Working Capital Per Executive | 13.3M |
Complementary Tools for Scpharmaceuticals Stock analysis
When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |